comparemela.com

Latest Breaking News On - Melanoma research program - Page 2 : comparemela.com

Dr Weber on Survival Outcomes With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

Jeffrey S. Weber, MD, PhD, discusses findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial of mRNA-4157 in combination with pembrolizumab in resected high-risk melanoma.

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr Jeffrey S Weber

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.